Bjoern D Suckow1, Larry W Kraiss2, Andres Schanzer3, David H Stone4, Jeffrey Kalish5, Randall R DeMartino4, Jack L Cronenwett4, Philip P Goodney4. 1. Division of Vascular Surgery, University of Utah School of Medicine, Salt Lake City, Utah. Electronic address: bjoern.suckow@hsc.utah.edu. 2. Division of Vascular Surgery, University of Utah School of Medicine, Salt Lake City, Utah. 3. Division of Vascular Surgery, University of Massachusetts Medical School, Worcester, Mass. 4. Section of Vascular Surgery, Geisel School of Medicine at Dartmouth, Hanover, NH. 5. Division of Vascular Surgery, Boston University School of Medicine, Boston, Mass.
Abstract
OBJECTIVE: Although statin therapy has been linked to fewer short-term complications after infrainguinal bypass, its effect on long-term survival remains unclear. We therefore examined associations between statin use and long-term mortality, graft occlusion, and amputation after infrainguinal bypass. METHODS: We used the Vascular Study Group of New England registry to study 2067 patients (71% male; mean age, 67 ± 11 years; 67% with critical limb ischemia [CLI]) who underwent infrainguinal bypass from 2003 to 2011. Of these, 1537 (74%) were on statins perioperatively and at 1-year follow-up, and 530 received no statin. We examined crude, adjusted, and propensity-matched rates of 5-year surviva1, 1-year amputation, graft occlusion, and perioperative myocardial infarction. RESULTS: Patients taking statins at the time of surgery and at the 1-year follow-up were more likely to have coronary disease (38% vs 22%; P < .001), diabetes (51% vs 36%; P < .001), hypertension (89% vs 77%; P < .001), and prior revascularization procedures (50% vs 38%; P < .001). Despite higher comorbidity burdens, long-term survival was better for patients taking statins in crude (risk ratio [RR], 0.7; P < .001), adjusted (hazard ratio, 0.7; P = .001), and propensity-matched analyses (hazard ratio, 0.7; P = .03). In subgroup analysis, a survival advantage was evident in patients on statins with CLI (5-year survival rate, 63% vs 54%; log-rank, P = .01) but not claudication (5-year survival rate, 84% vs 80%; log-rank, P = .59). Statin therapy was not associated with 1-year rates of major amputation (12% vs 11%; P = .84) or graft occlusion (20% vs 18%; P = .58) in CLI patients. Perioperative myocardial infarction occurred more frequently in patients on a statin in crude analysis (RR, 2.2; P = .01) but not in the matched cohort (RR, 1.9; P = .17). CONCLUSIONS: Statin therapy is associated with a 5-year survival benefit after infrainguinal bypass in patients with CLI. However, 1-year limb-related outcomes were not influenced by statin use in our large observational cohort of patients undergoing revascularization in New England.
OBJECTIVE: Although statin therapy has been linked to fewer short-term complications after infrainguinal bypass, its effect on long-term survival remains unclear. We therefore examined associations between statin use and long-term mortality, graft occlusion, and amputation after infrainguinal bypass. METHODS: We used the Vascular Study Group of New England registry to study 2067 patients (71% male; mean age, 67 ± 11 years; 67% with critical limb ischemia [CLI]) who underwent infrainguinal bypass from 2003 to 2011. Of these, 1537 (74%) were on statins perioperatively and at 1-year follow-up, and 530 received no statin. We examined crude, adjusted, and propensity-matched rates of 5-year surviva1, 1-year amputation, graft occlusion, and perioperative myocardial infarction. RESULTS:Patients taking statins at the time of surgery and at the 1-year follow-up were more likely to have coronary disease (38% vs 22%; P < .001), diabetes (51% vs 36%; P < .001), hypertension (89% vs 77%; P < .001), and prior revascularization procedures (50% vs 38%; P < .001). Despite higher comorbidity burdens, long-term survival was better for patients taking statins in crude (risk ratio [RR], 0.7; P < .001), adjusted (hazard ratio, 0.7; P = .001), and propensity-matched analyses (hazard ratio, 0.7; P = .03). In subgroup analysis, a survival advantage was evident in patients on statins with CLI (5-year survival rate, 63% vs 54%; log-rank, P = .01) but not claudication (5-year survival rate, 84% vs 80%; log-rank, P = .59). Statin therapy was not associated with 1-year rates of major amputation (12% vs 11%; P = .84) or graft occlusion (20% vs 18%; P = .58) in CLI patients. Perioperative myocardial infarction occurred more frequently in patients on a statin in crude analysis (RR, 2.2; P = .01) but not in the matched cohort (RR, 1.9; P = .17). CONCLUSIONS: Statin therapy is associated with a 5-year survival benefit after infrainguinal bypass in patients with CLI. However, 1-year limb-related outcomes were not influenced by statin use in our large observational cohort of patients undergoing revascularization in New England.
Authors: M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner Journal: N Engl J Med Date: 1992-02-06 Impact factor: 91.245
Authors: R Parker Ward; Nicholas J Leeper; James N Kirkpatrick; Roberto M Lang; Matthew J Sorrentino; Kim A Williams Journal: Int J Cardiol Date: 2005-10-10 Impact factor: 4.164
Authors: Thomas F Rehring; Brian G Sandhoff; Ryan S Stolcpart; John A Merenich; H Whitton Hollis Journal: J Vasc Surg Date: 2005-05 Impact factor: 4.268
Authors: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn Journal: N Engl J Med Date: 2008-11-09 Impact factor: 91.245
Authors: Andres Schanzer; Nathanael Hevelone; Christopher D Owens; Joshua A Beckman; Michael Belkin; Michael S Conte Journal: J Vasc Surg Date: 2008-04 Impact factor: 4.268
Authors: Jack L Cronenwett; Donald S Likosky; Margaret T Russell; Jens Eldrup-Jorgensen; Andrew C Stanley; Brian W Nolan Journal: J Vasc Surg Date: 2007-10-24 Impact factor: 4.268
Authors: Alan T Hirsch; Ziv J Haskal; Norman R Hertzer; Curtis W Bakal; Mark A Creager; Jonathan L Halperin; Loren F Hiratzka; William R C Murphy; Jeffrey W Olin; Jules B Puschett; Kenneth A Rosenfield; David Sacks; James C Stanley; Lloyd M Taylor; Christopher J White; John White; Rodney A White; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Sharon A Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-03-21 Impact factor: 29.690
Authors: Ali F AbuRahma; Mohit Srivastava; Patrick A Stone; Bryan K Richmond; Zachary AbuRahma; Will Jackson; L Scott Dean; Albeir Y Mousa Journal: J Am Coll Surg Date: 2014-12-15 Impact factor: 6.113
Authors: Benjamin S B Rasmussen; Knud B Yderstraede; Bendix Carstensen; Ole Skov; Henning Beck-Nielsen Journal: Diabetologia Date: 2015-11-22 Impact factor: 10.122
Authors: Jin F Chen; Nathaniel R Smilowitz; Jung T Kim; Germaine Cuff; Alina Boltunova; Jason Toffey; Jeffrey S Berger; Andrew Rosenberg; Samir Kendale Journal: Int J Cardiol Date: 2018-12-12 Impact factor: 4.164